인쇄하기
취소

KFDA not allows 3 COX-2 inhibitors to register.

Published: 2005-12-29 06:59:00
Updated: 2005-12-29 06:59:00
Amid the safety problem of Celebrex, a COX-2 inhibitor, the KFDA said on Dec. 26 that the clinical studies of Bextra 100mg and 200mg (baldecoxcib) and the health registation of Palecoxib (Dynastat inj.) should not be allowed due to the risk of cardiovascular problems.

The KFDA's measure seems to link with the cardiovascular problems of Vioxx (Ropecoxib) in Oct. last year, which caused its m...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.